

B15 6. (Once Amended) The antibody of claim 4, further characterized as having the specificity of a monoclonal antibody produced by a hybridoma cell line having ATCC accession number HB12570.

B16 8. (Once Amended) The antibody of claim 2, wherein the antibody is humanized.

Antibody CS
B17 10. (Once Amended) The antibody of claim 9, which preferentially binds an eight amino acid epitope having the sequence QSRDTEVL (SEQ ID NO: 1), or an eight amino acid epitope having an analog sequence of the sequence QSRDTEVL (SEQ ID NO: 1), of the ECRT/DEP-1 ectodomain.

B18 12. (Once Amended) The antibody of claim 8, wherein the humanized antibody is further characterized as having the specificity of a monoclonal antibody produced by a hybridoma cell line having ATCC accession number HB12570.

B19 13. (Once Amended) The antibody of claim 12, where the humanized antibody is a monoclonal antibody produced by a hybridoma cell line having ATCC accession number HB12570.

14. (Once Amended) The antibody of claim 2, in a pharmaceutically acceptable diluent or excipient.

Please add the following new claims:

B20 45. (New) The antibody of claim 2, which has activity in the modulation of angiogenesis.

46. (New) The antibody of claim 8, which has activity in the modulation of angiogenesis.

47. (New) The antibody of claim 2, wherein the antibody fragment is selected from the group consisting of an Fab fragment, an Fab' fragment, an F(ab')₂ fragment and an F(v) fragment.

48. (New) The antibody of claim 47, wherein the F(v) fragment is an scFv fragment.

49. (New) The antibody of claim 4, wherein the antibody fragment is selected from the group consisting of an Fab fragment, an Fab' fragment, an F(ab')₂ fragment and an F(v) fragment.

50. (New) The antibody of claim 49, wherein the F(v) fragment is an scFv fragment.

51. (New) The antibody of claim 8, wherein the antibody fragment is selected from the group consisting of an Fab fragment, an Fab' fragment, an F(ab')₂ fragment and an F(v) fragment.

B20
cont

52. (New) The antibody of claim 51, wherein the F(v) fragment is an scFv fragment.

53. (New) The antibody of claim 3, which binds an eight amino acid epitope having the sequence QSRDTEVL (SEQ ID NO: 1).

54. (New) The antibody of claim 10, which binds an eight amino acid epitope having the sequence QSRDTEVL (SEQ ID NO: 1).

55. (New) An antibody having the specificity of an antibody produced by the hybridoma cell line having ATCC accession number HB12570.